Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010;15(2):182-6.
doi: 10.1634/theoncologist.2009-0297. Epub 2010 Feb 2.

Why doesn't imatinib cure chronic myeloid leukemia?

Robert L Redner  1
Affiliations
Review

Why doesn't imatinib cure chronic myeloid leukemia?

Robert L Redner. Oncologist. 2010.

Abstract

Imatinib mesylate has transformed the treatment for chronic myeloid leukemia (CML). The vast majority of patients obtain hematologic remission, with a low probability of progression of disease. Yet imatinib rarely cures CML, and current recommendations dictate lifelong treatment with imatinib. In this review we analyze the biology behind the failure of imatinib to fully eradicate CML. We review evidence that indicates that the leukemic stem cell for CML is inherently resistant to imatinib, and that imatinib treatment itself may enhance this resistance.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Robert L. Redner: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the author or independent peer reviewers.

Figures

Figure 1.
Figure 1.
Factors that may play a role in determining the inherent resistance of CML leukemia-initiating cells to imatinib. Abbreviations: ABCG2, ATP-dependent transporter cassette protein G2; CML, chronic myeloid leukemia; CXCR4, CXC chemokine receptor 4.
See this image and copyright information in PMC

References

    1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808–4817. - PubMed
    1. Goldman JM. Advances in CML. Clin Adv Hematol Oncol. 2007;5:270–272. 292. - PubMed
    1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. - PubMed
    1. Kantarjian HM, Cortes JE, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood. 2004;104:1979–1988. - PubMed
    1. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425–3432. - PubMed

MeSH terms